Supriya Lifescience Limited has informed the Exchange regarding a press release dated May 28, 2026, titled "Press Release - Audited Financial Results for quarter and year ended March 31, 2026".
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Supriya Lifescience reported strong Q4FY26 results with revenue surging 50.2% year-over-year to Rs 276.53 crore, driven by the anaesthetic segment (54% of revenues). Full-year FY26 revenue grew 18.9% to Rs 827.87 crore. PAT for Q4 rose 47.4% to Rs 74.23 crore and full-year PAT increased 11.3% to Rs 209.12 crore. However, both EBITDA and PAT margins compressed during the year — EBITDA margin fell from 37.4% to 35.5% in FY26, and PAT margin declined from 27.0% to 25.3%. Capacity utilisation improved to 74% from 70%, supported by ramp-up at the Lote facility. The company also expanded its Ambernath formulation facility and made strategic land acquisitions for future growth.
While Supriya Lifescience delivered robust topline growth and strong profitability, the margin compression during FY26 may raise concerns about cost pressures. The impressive 50% Q4 revenue growth and expansion into new product categories like cardiovascular and ADHD segments are positive signals for long-term shareholders.